Update on extended release quetiapine fumarate in schizophrenia and bipolar disorders.

摘要: The atypical antipsychotic quetiapine fumarate is available both as an immediate release (IR) and extended (XR) formulation allowing flexibility of dosing for individual patients. Approved uses XR include the treatment schizophrenia (including maintenance therapy prevention relapse), bipolar disorder (manic depressive episodes), recurrence in patients with who respond to XR. This narrative review provides update on these indications. pharmacological profile quetiapine, including a moderate affinity dopamine D2 receptors higher serotonin 5-hydroxytryptophan (5-HT)2A receptors, may explain its broad efficacy low propensity extrapyramidal symptoms (EPS). has similar bioavailability but prolonged plasma levels compared IR formulation, less frequent (once-daily) dosing. Clinical studies have confirmed relieving acute during short-term trials, reducing risk relapse long-term studies. Direct switching from same dose did not reveal any loss or tolerability issues, conventional other antipsychotics (for reasons insufficient tolerability) also proved be beneficial generally well tolerated. In disorder, proven effective manic symptoms. Adverse events either are those associated most common being sedation, dry mouth, somnolence, dizziness, headache. EPS maintained formulation. Overall, evidence clinical trials suggests that well-tolerated option disorder.